The discovery of the breast and ovarian cancer predisposition genes, BRCA1 and BRCA2, has led to the development of lifesaving treatments and cancer risk reduction strategies in families who carry pathogenic variants. Genetic testing techniques have improved over the years and decreased in cost so that many who meet widely accepted testing guidelines based on family and personal histories of cancer are able to afford testing after appropriate counseling. It has been suggested that all women should be offered genetic testing for these genes, regardless of family or personal cancer history. To implement a population-based screening program, primary care physicians would need to know about the BRCA genes as well as understand how best to us...
Recent advances in human genetics have led to a plethora of interest in understanding how genetic te...
AbstractBackgroundGenetic testing for cancer susceptibility is an emerging technology in medicine. T...
We prospectively screened a hospital-based population of 1000 successive breast cancer patients rece...
The discovery of the breast and ovarian cancer predisposition genes, BRCA1 and BRCA2, has led to the...
BACKGROUND: Genetic testing for cancer susceptibility is an emerging technology in medicine. This st...
Hereditary breast and ovarian cancer (HBOC) is an inherited cancer syndrome that is associated with ...
This project seeks to support the clinical practice of using established guidelines for evaluating w...
Physicians currently consider genetic testing for breast cancer, especially the BRCA1 and BRCA2 test...
Background: Primary health care providers are expected to be directly involved in the genetic testin...
BRCA1 and BRCA2 are gene mutations that drastically increase chances of developing breast and ovaria...
The localisation of the two breast cancer susceptibility genes BRCA1 and BRCA2 made possible the use...
Background: Breast and ovarian cancer can arise from genetic predisposition and environmental (i.e.,...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
Background: Cancer genetic testing guides disease surveillance in those with moderate to high cancer...
Published online: 29 September 2010The responsibility for informing at-risk relatives of the availab...
Recent advances in human genetics have led to a plethora of interest in understanding how genetic te...
AbstractBackgroundGenetic testing for cancer susceptibility is an emerging technology in medicine. T...
We prospectively screened a hospital-based population of 1000 successive breast cancer patients rece...
The discovery of the breast and ovarian cancer predisposition genes, BRCA1 and BRCA2, has led to the...
BACKGROUND: Genetic testing for cancer susceptibility is an emerging technology in medicine. This st...
Hereditary breast and ovarian cancer (HBOC) is an inherited cancer syndrome that is associated with ...
This project seeks to support the clinical practice of using established guidelines for evaluating w...
Physicians currently consider genetic testing for breast cancer, especially the BRCA1 and BRCA2 test...
Background: Primary health care providers are expected to be directly involved in the genetic testin...
BRCA1 and BRCA2 are gene mutations that drastically increase chances of developing breast and ovaria...
The localisation of the two breast cancer susceptibility genes BRCA1 and BRCA2 made possible the use...
Background: Breast and ovarian cancer can arise from genetic predisposition and environmental (i.e.,...
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances ...
Background: Cancer genetic testing guides disease surveillance in those with moderate to high cancer...
Published online: 29 September 2010The responsibility for informing at-risk relatives of the availab...
Recent advances in human genetics have led to a plethora of interest in understanding how genetic te...
AbstractBackgroundGenetic testing for cancer susceptibility is an emerging technology in medicine. T...
We prospectively screened a hospital-based population of 1000 successive breast cancer patients rece...